Over 85% of Patients Diagnosed with Chronic Hepatitis C in the U.S. Are Currently NOT Receiving Treatment
Argentina SOF Prodrug Decision
Amicus Brief Filed in Oil States vs. Greene Energy Group Supreme Court Case: The Critical Role of Patent Challenges in Increasing Competition and Reducing Drug Prices
In 2011, Congress passed the Leahy-Smith America Invents Act (“AIA”) to curb the spread of unmerited patents, stop abusive litigation, and ensure a fair playing field for patent applicants. Leahy-Smith America Invents Act, Pub. L. No. 112- 20, 125 Stat. 284, 35 U.S.C. § 1 et seq. (2011). In the face of industry overreliance on…
America’s Overspend: How the Pharmaceutical Patent Problem is Fueling High Drug Prices
The American health system is poised to incur $55 billion in excess costs from pharmaceutical companies’ strategies to delay competition on three drugs
The critical role of civil society in shaping the market for antiretroviral therapy and direct-acting antivirals
Civil society – in particular people living with and affected by HIV/AIDS – helped shape the market for antiretroviral drugs in low- and middle-income countries. There is a critical need to support civil society interventions that will similarly impact treatment access for hepatitis C.
Hepatitis C
Data from Patent Landscape Report for Pegylated Interferon Alfa 2A & 2B
Patent Landscape Report For Pegylated Interferon Alfa 2A & 2B